Literature DB >> 12186916

Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry.

Miriam Triyatni1, Bertrand Saunier, Padma Maruvada, Anthony R Davis, Luca Ulianich, Theo Heller, Arvind Patel, Leonard D Kohn, T Jake Liang.   

Abstract

Hepatitis C virus-like particles (HCV-LPs) containing the structural proteins of HCV H77 strain (1a genotype) was used as a model for HCV virion to study virus-cell interaction. HCV-LPs showed a buoyant density of 1.17 to 1.22 g/cm(3) in a sucrose gradient and formed double-shelled particles 35 to 49 nm in diameter. Flow cytometry analysis by an indirect method (detection with anti-E2 antibody) and a direct method (use of dye-labeled HCV-LPs) showed that HCV-LPs binds to several human hepatic (primary hepatocytes, HepG2, HuH7, and NKNT-3) and T-cell (Molt-4) lines. HCV-LPs binding to cells occurred in a dose- and calcium-dependent manner and was not mediated by CD81. Scatchard plot analysis suggests the presence of two binding sites for HCV-LPs with high (K(d) approximately 1 microg/ml) and low (K(d) approximately 50 to 60 microg/ml) affinities of binding. Anti-E1 and -E2 antibodies inhibited HCV-LPs binding to cells. While preincubation of HCV-LPs with very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), or high-density lipoprotein (HDL) blocked its binding to cells, preincubation of cells with VLDL, LDL, HDL, or anti-LDL-R antibody did not. Confocal microscopy analysis showed that, after binding to cells, dye-labeled HCV-LPs were internalized into the cytoplasm. This process could be inhibited with anti-E1 or anti-E2 antibodies, suggesting that E1 and E2 proteins mediate HCV-LPs binding and, subsequently, their entry into cells. Altogether, our results indicate that HCV-LPs can be used to further characterize the mechanisms involved in the early steps of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186916      PMCID: PMC136469          DOI: 10.1128/jvi.76.18.9335-9344.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Ultrastructural observations in hepatitis C virus-infected lymphoid cells.

Authors:  A Steffan; P Marianneau; C Caussin-Schwemling; C Royer; C Schmitt; D Jaeck; P Wolf; J Gendrault; F Stoll-Keller
Journal:  Microbes Infect       Date:  2001-03       Impact factor: 2.700

2.  Physical interaction of human papillomavirus virus-like particles with immune cells.

Authors:  D M Da Silva; M P Velders; J D Nieland; J T Schiller; B J Nickoloff; W M Kast
Journal:  Int Immunol       Date:  2001-05       Impact factor: 4.823

3.  Synthesis of rotavirus-like particles in insect cells: comparative and quantitative analysis.

Authors:  B Jiang; V Barniak; R P Smith; R Sharma; B Corsaro; B Hu; H P Madore
Journal:  Biotechnol Bioeng       Date:  1998-11-05       Impact factor: 4.530

4.  Cell fusion activity of hepatitis C virus envelope proteins.

Authors:  S Takikawa; K Ishii; H Aizaki; T Suzuki; H Asakura; Y Matsuura; T Miyamura
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Biochemical requirements of virus wrapping by the endoplasmic reticulum: involvement of ATP and endoplasmic reticulum calcium store during envelopment of African swine fever virus.

Authors:  C Cobbold; S M Brookes; T Wileman
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

7.  Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.

Authors:  A Higginbottom; E R Quinn; C C Kuo; M Flint; L H Wilson; E Bianchi; A Nicosia; P N Monk; J A McKeating; S Levy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines.

Authors:  S Hamaia; C Li; J P Allain
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

9.  Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

Authors:  M Hijikata; Y K Shimizu; H Kato; A Iwamoto; J W Shih; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

Authors:  Stefania Crotta; Annalisa Stilla; Andreas Wack; Annalisa D'Andrea; Sandra Nuti; Ugo D'Oro; Marta Mosca; Franco Filliponi; R Maurizia Brunetto; Ferruccio Bonino; Sergio Abrignani; Nicholas M Valiante
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  35 in total

1.  Flow cytometric detection of hepatitis C virus antigens in infected peripheral blood leukocytes: binding and entry.

Authors:  Mostafa K el-Awady; Ashraf A Tabll; el-Rashdy M Redwan; Samar Youssef; Moataza H Omran; Fouad Thakeb; Maha el-Demellawy
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

Review 2.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 3.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

4.  Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes.

Authors:  Bertrand Saunier; Miriam Triyatni; Luca Ulianich; Padma Maruvada; Paul Yen; Leonard D Kohn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro.

Authors:  Mostafa K el-Awady; Ashraf A Tabll; Yasmine S el-Abd; Mahmoud M Bahgat; Hussein A Shoeb; Samar S Youssef; Noha G Bader el-Din; el-Rashdy M Redwan; Maha el-Demellawy; Moataza H Omran; Wael T el-Garf; Said A Goueli
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

6.  Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.

Authors:  Pierluigi Toniutto; Carlo Fabris; Claudio Avellini; Rosalba Minisini; Davide Bitetto; Elisabetta Rossi; Carlo Smirne; Mario Pirisi
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

7.  Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.

Authors:  Rachel Eren; Dorit Landstein; Dov Terkieltaub; Ofer Nussbaum; Arie Zauberman; Judith Ben-Porath; Judith Gopher; Rachel Buchnick; Riva Kovjazin; Ziva Rosenthal-Galili; Sigal Aviel; Ehud Ilan; Yariv Shoshany; Lewis Neville; Tal Waisman; Ofer Ben-Moshe; Alberto Kischitsky; Steven K H Foung; Zhen-Yong Keck; Orit Pappo; Ahmed Eid; Oded Jurim; Gidi Zamir; Eithan Galun; Shlomo Dagan
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 8.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.

Authors:  Takayoshi Shirasaki; Masao Honda; Tetsuro Shimakami; Rika Horii; Taro Yamashita; Yoshio Sakai; Akito Sakai; Hikari Okada; Risa Watanabe; Seishi Murakami; MinKyung Yi; Stanley M Lemon; Shuichi Kaneko
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.

Authors:  Zhen-Yong Keck; Vicky M H Sung; Susan Perkins; Judy Rowe; Sudhir Paul; T Jake Liang; Michael M C Lai; Steven K H Foung
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.